Fuse Unveils Mark: AI Revolutionizes Commercial Insurance Submissions
Fuse has introduced Mark, an AI-driven submission scoring system built to address information asymmetry and slow manual workflows in commercial insurance. Mark ingests broker submissions and attached documents, applies natural language processing and structured data extraction, then produces an objective score that signals market readiness and underwriting fit.
Solving the Information Imbalance
Commercial submissions often arrive inconsistent or incomplete, forcing underwriters to chase details and rely heavily on experience. Mark tackles this by standardizing intake and surfacing the most relevant signals from applications, ACORD forms, claims histories, financials and other attachments. The result is a clearer, faster assessment of whether a risk should proceed to quote or needs additional information.
How Mark Leverages AI and Live Data
Mark combines NLP and rules-based extraction with live market intelligence from more than 50 data sources. Submissions pass through a five-stage evaluation framework that checks completeness, identifies risk indicators, measures market fit, evaluates pricing signals and reviews documentation quality. The system then generates a score and an actionable summary for brokers and underwriters, including recommended next steps and comparable market context.
The Future of Efficient Underwriting
For brokers, Mark shortens placement cycles by highlighting submission gaps before carrier review and by signaling which markets are likely to respond. For carriers and MGAs, it reduces manual triage, increases quote throughput and improves consistency in underwriting decisions. Available as a trial with tiered plans, Mark illustrates how AI and real-time market data can bring objectivity and velocity to a historically opaque process.
As InsurTech tools like Mark mature, expect submission evaluation to shift from intuition-driven reviews to data-driven workflows that free professionals to focus on complex underwriting and client strategy.
